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Background & Objective: Acinetobacter baumannii is a Gram-negative coccobacillus and one of the most 
opportunistic pathogens responsible for serious infections in hospitalized patients. 
Materials and Methods: During a 12 months study, 221 clinical isolates and 22 environmental Acinetobacter 
baumannii isolates were collected. In vitro susceptibility of Acinetobacter baumannii isolates to 13 antimicrobial 
agents: amikacin; cefepime; ceftazidime; ciprofloxacin; meropenem; piperacillin/tazobactam; sulfamethoxazole/ 
trimethoprim; imipenem; tigecycline; colistin; gentamycin; ceftriaxone; levofloxacin was performed by the disk 
diffusion method. Also Minimum Inhibitory Concentration (MICs) of imipenem; levofloxacin and cefepime was 
performed by the E-test according to Clinical and Laboratory Standards Institute (CLSI) criteria. blaOXA-23, blaOXA- 
24, blaOXA-58, blaOXA-51 genes were detected by polymerase chain reaction and sequencing. 
Results: The result of antimicrobial susceptibility test of clinical isolates by the disk diffusion method revealed 
that all strains of Acinetobacter baumannii were resistant to piperacillin/tazobactam. The rates of resistance to the 
majority of antibiotics tested varied between 69% and 100 %, with the exception of tigecycline and colistin. Of 
221 isolates tested 99(44.8%) were XDR. All strains carried a blaOXA-51-like gene. blaOXA-23 gene was the most 
prevalent among blaOXA-types 
Conclusion: Colistin and tigecycline can be effective drugs for treatment of Acinetobacter baumannii infections. 
Continuous Surveillance for Acinetobacter baumannii multidrug-resistant strains is necessary to prevent the 
further spread of resistant isolates. 
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vegetables, meat, and fish 
1. 
A. baumannii is responsible 
 
A. baumannii is a Gram-negative coccobacillus and one 
of the most opportunistic pathogens responsible for 
serious infections. This organism is found frequently as a 
skin and throat commensal in humans and also in various 
environmental sources such as soil and foods, including 
for a spectrum of infections that can range from urinary 
or wound infections to peritonitis, endocarditis, 
cerebrospinal meningitis and septicaemia 
2
. A. 
baumannii is a fastidious organism able to grow at 
various temperatures and pH conditions. It can survive in 
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propensity to develop resistance to antimicrobial agents 
3
. During the past decade, A. baumannii exhibited a 
remarkable ability to rapidly develop antibiotic 
resistance. Resistance to antimicrobial agents among A. 
baumannii  clinical  isolates  is  higher  than  community 
isolates   
4
.   A.   baumannii   possesses   mechanisms   of 
resistance to most of antibiotic classes, as well as a great 
propensity for developing mechanisms of drug resistance 
rapidly. To date, some strains of A. baumannii have 
become almost resistant to all currently available 
antibacterial agents and thus, empirical treatment choices 
are extremely limited 
5
. The most prevalent resistance- 
related determinants in multi-drug resistant A. baumannii 
include genes for AmpC cephalosporinases, OXA-type 
carbapenemases, metallo-_-lactamases (MBLs), efflux 
pumps and integrons. Carbapenems are the first choice 
in the treatment of severe A. baumannii infections. 
Unfortunately, resistance to Carbapenems among A. 




The resistance to carbapenems is due to carbapenem- 
hydrolysing β-lactamase enzymes of Ambler molecular 
class B (metallo-β-lactamases) and D (oxacillinases). 
The OXA-type carbapenemases have emerged globally 
as the main mechanism responsible for this resistance. 
Currently, OXA-type carbapenemases are classified into 
eight subgroups and four of them were identified in A. 
baumannii: OXA-23, OXA-24, OXA-58, and OXA-51– 
like enzymes. Recently it has been suggested that 
enzymes belonging to the OXA-51-like subgroup are 
intrinsic to A. baumannii. blaOXA-51-like type genes are 
intrinsically harbored by A. baumannii and exhibit 
presence of a direct reservoir of β-lactam-resistance 
genes. Detection of blaOXA can be used as a simple and 
reliable  method  to  differentiate  A.  baumannii  strains 
from other species 
8, 9, 10, 11
. The study of resistance to 
this group of antimicrobials to treatment of infected 
patients with A.baumannii is therefore essential. The aim 
of this study was to investigate the antimicrobial 
susceptibility patterns of A. baumannii carrying blaoxA 




Materials and Methods 
 
Bacterial isolates 
A total of 221 clinical isolates of A.baumannii which 
were recovered from specimens of patients suspected 
with A.baumannii infection and 22 environmental 
isolates which were obtained from patients’ 
surroundings, medical equipment and hands of staff 
during November 2010 to Oct 2011 were included in this 
study. A questionnaire containing different clinical and 
personal data i.e. clinical symptoms, antibiotic usages 
and underlying conditions was completed for all persons. 
All the patient and environment samples  were 
transported to the Microbiology Research Laboratory in 
the Department of Microbiology and were processed 
immediately. Samples were streaked across MacConkey 
and blood agar plates for all specimens as routine, 
Trypticase Soy Broth (TSB), and sub-cultured on 
chocolate agar for blood specimens, and chocolate agar 
for specimens other than urine. Presumptive 
identification was done based on culture characteristics 
and gram stain. According to Conventional biochemical 
tests, typical reaction of A. baumanni to glucose is 
positive and to oxidase, mannitol, maltose, Esculin, 
Indole, and H2S are negative. A. baumannii has also 
ALK/ALK reaction on Triple sugar iron (TSI) agar 
12
. 
Standard identification, confirmation and complete 
method was conducted including using API® 20E 
(bioMérieux, France) the commercial identification 
system. Non A. baumannii isolates were excluded from 
the study. Samples confirmed as a A.baumannii were 
stored in Tryptic Soy Broth (TSB; Merck, Germany) 
containing 20% glycerol at -70°C and were subjected to 
further molecular identification. 
Antimicrobial susceptibility testing 
To evaluate antimicrobial susceptibility of A.baumannii 
isolates, Disk diffusion method was performed according 
to Clinical Laboratory and Standards Institute (CLSI; 
formerly  National  Committee  for  Clinical  Laboratory 
Standards) criteria 
13
. The following antimicrobial agents 
were used in this study: amikacin; cefepime; 
ceftazidime; ciprofloxacin; meropenem; 
piperacillin/tazobactam;  sulfamethoxazole/ 
trimethoprim; imipenem; tigecycline; colistin; 
gentamycin; ceftriaxone; levofloxacin. Antibiotic disks 
used in this research were supplied by MAST 
Laboratories Ltd (Bootle, Merseyside, UK). Briefly, a 
bacterial suspension was obtained from overnight 
cultures. The turbidity of each bacterial suspension was 
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adjusted equivalent to a no. 0.5 McFarland standard and 
then inoculated on Mueller-Hinton agar (Oxoid, UK). 
Diameter of inhibition zones was measured after 
incubation at 35ºC for 18-24 hours, and data were 
reported as susceptible, intermediate, and resistant. 
Escherichia coli ATCC 25922 and Pseudomonas 
aeruginosa ATCC 27853 were used as reference strains 
for susceptibility testing 
Minimum Inhibitory Concentration (MIC) 
The antimicrobial susceptibility profile for all isolates 
was determined by estimating MIC of 3 antibiotics using 
E test method according CLSI; interpretive standards 
13
. 
The MIC was defined as the lowest concentration of 
each antimicrobial agent that inhibited visible growth of 
the tested isolate. The following antimicrobial agents 
were used in this study: imipenem; levofloxacin and 
cefepime (AB BIODISK, Solna, Sweden). The ranges of 
MIC value used for antimicrobial agents included: 
imipenem 0.38 to 32 µg/ml; levofloxacin 3 to 256 µg/ml 
and cefepime 0.064 to 32 µg/ml. Briefly, ta bacterial 
suspension was obtained from overnight cultures. The 
turbidity of each of them was adjusted equivalent to a 
no. 0.5 McFarland standard inoculated on Mueller- 
Hinton plates, then E test strips were placed on 
inoculated plates. Plates were incubated at 37° C for 24 
h. All plates were monitored daily. The MIC value was 
read where the ellipse of growth inhibition intersects the 
strip. Antibiotic resistance was defined as follows: 
MIC≥32 µg/ml for imipenem, MIC≥ 16 µg/ml for 
imipenem, MIC≥8 µg/ml for levofloxacin, according to 




DNA extraction and PCR of blaOXA genes: 
DNA was extracted from bacteria on nutrient agar 
medium by Using QIAamp DNA isolation columns 
(Qiagen, Hilden, Germany) according to the 
manufacturer’s procedure. The presence of OXA-type 
genes was detected by PCR as described previously by 
Turton et al. and Niel et al 
14, 15
. Primer sequences used 
for detection of blaOXA-51-like, blaOXA -23- like, 
blaOXA -24- like and blaOXA-58-like and their 
fragment size are presented in Table 1. The PCR 
reactions for detection blaOXA types genes were done 
on a total volume of 25 µL. The reaction mixture 
contained 1x buffer (10 mM Tris-HCl, 50 mM KCl), 1.5 
mM MgCl2, 0.2µM of each deoxynucleoside 
triphosphate, 0.5µM of primers and 1.5 U of Takara Taq 
(Takara Shuzo Co., Ltd., Shiga, Japan). For 
amplification of 412 bp fragment of the tcdB gene the 
following time-temperature profile was used: 5 min at 
94ºC for initial denaturation, 35 cycles of 1min at 94 ºC, 
1 min at 51 ºC, and 80s at 72 ºC ; and a final extension 
cycle of 5 min at 72 ºC. Amplified fragments were 
separated by 1.2% agarose gel electrophoresis at 80V for 
2h  
16
.  Finally,  fragments  were  stained  by  ethidium 
bromide and detected under UV light. 
 
 








5´-TAA TGC TTT GAT CGG CCT TG-3´ 




blaOXA -23- like 
5´GAT CGG ATT GGA GAA CCA GA-3´ 
5´ ATT TCT GAC CGC ATT TCC AT-3´ 
 
501 
blaOXA       -24- 
like 
5´-GGT TAG TTG GCC CCC TTA AA-3´ 





5´-AAG TAT TGG GGC TTGTGC TG-3´ 







Overall, 221 strains of A. baumannii were isolated from 
hospitalized patients in 3 hospitals. The patients were 
distributed in 10 hospital departments. Sixty percent 
(n=108) of the isolates were from males. The median age 
was 55.1 years old and patient age ranged from 1month 
to 90 years old. Most A. baumannii were isolated from 
the ICU (75.1%). Isolates were most frequently 
recovered from respiratory secretions (n=129) followed 
by wound (n=25), blood (n=24), urine (n=19), catheter 
(n=11), cerebrospinal fluid (n=4), eye (n=2) and other 
body fluid (n=7). 
The result of antimicrobial susceptibility test of clinical 
isolates by the disk diffusion method revealed that all 
strains of A. baumannii were resistant to 
piperacillin/tazobactam. The majority of isolates were 
resistant   to   Cefepime   (99%),   ceftazidime   (99%), 
ciprofloxacin (98%), meropenem (99%), 
sulfamethoxazole/ trimethoprim (99%), imipenem 
(91.5%), ceftriaxone (99%), levofloxacin (96.5%), 
amikacin (70%) and gentamycin (85%). The rates of 
resistance  to  the  majority  of  antibiotics  tested  varied 
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OXA-type A. baumannii isolates 




blaOXA-23-like 123(55.7) 98(44.3) 
blaOXA -58-like 28(12.7) 193(87.3) 
blaOXA -24-like 3(1.4) 218(98.6) 
blaOXA    -58/  blaOXA    -23- 
like 
15(6.8) 206(93.2) 
blaOXA    -23/  blaOXA    -24- 
like 
1(0.5) 220(99.5) 






















32 32 7(3.1) 0(0) 214(96.8)  


























































between 69% and 100 %, with the exception of 
tigecycline (4%) and colistin (0%). Antimicrobial 
susceptibilities of 221 A. baumannii isolates to 13 
antimicrobial are shown in figure 1. MDR A. baumannii 
was defined as those resistant to 3 or more different 
classes of antibiotics while extensively drug-resistant 
(XDR) A. baumannii was defined as the isolates that 
were resistant to all tested antibiotics except colistin and 
tigecycline  
17
.  Of  221  isolates tested  99(44.8%)  were 
XDR. XDR strains to three or more tested antibiotics 
were isolates from hospitalized patients in ICU, Surgery, 
internal medicine and infectious wards. 
PCR results for detection of 4 types of blaOXA genes 
showed that all strains carry a blaOXA-51-like gene, 
confirming the strain identification (Figure 2). The 
presence of blaOXA-23 was confirmed in 123 (55.7%) 
(Figure 3), blaoxa-58 in 28 (12.7%) (Figure 4), blaOXA-24 
in 3 (1/4%) strains (Figure 5). The co-existence of 
blaOXA-58 and blaOXA-23 were detected in 15 (6.8%) 
isolates and blaOXA-23-like and blaOXA-24 in 1 (0.5%). 
There is no co-existence of blaOXA-24-like and blaOXA-58 
among isolates. The frequency of blaOXA-types among 

























Figure1. Antimicrobial susceptibilities of 221 A. baumannii isolates to 13 
antimicrobial 
 
In vitro susceptibility of the A.baumannii isolates to 3 
antibiotics tested and the range of Minimum Inhibitory 
Concentration required to inhibit the growth of 50% of 
organisms (MIC50) and Minimum Inhibitory 
Concentration required to inhibit the growth of 90% of 
organisms (MIC90) are summarized in Table 2. 
 














a MIC breakpoints applied were those recommended for anaerobes by the 
Clinical and Laboratory Standards Institute 13 
Figure 2. Detection of genes encoding blaOXA -51 in A. baumannii by 
PCR. M, 100 pb DNA ladder (Fermentas); G+, positive control; 1-4, 
representative strains tested and G-, negative control. 
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Figure 3. Detection of genes encoding blaOXA -23 in A. baumannii by 
PCR. M, 100 pb DNA ladder (Fermentas); G+, positive control; 1-4, 




Figure 4. Detection of genes encoding blaOXA -58 in A. baumannii by PCR. 
M, 100 pb DNA ladder (Fermentas); G+, positive control; 1and 2, 




Figure 5. Detection of genes encoding blaOXA -24 in A. baumannii by PCR. 
M, 100 pb DNA ladder (Fermentas); G+, positive control; 1-9, 






A. baumannii has become an important pathogen in 
recent years and has been shown to increase morbidity 
and mortality. A. baumannii are a cause of healthcare- 
associated and nosocomial infections. They are widely 
distributed in nature. Control of A. baumannii infections 




Studies performed by several investigators exhibited that 
resistance patterns among nosocomial  bacterial 
pathogens is increasing and varies from one geographic 
region to another. 
In this study we studied susceptibility pattern of the 221 
clinical and 22 environmental isolates of A. baumannii to 
13 different antibiotics as common therapeutic drugs in 
hospitalized patients. 
Our findings showed that all strains were resistant to 
piperacillin/tazobactam. The rates of resistance to the 
majority of antibiotics (Cefepime, ceftazidime, 
ciprofloxacin, meropenem, sulfamethoxazole/ 
trimethoprime, imipenem, ceftriaxone, levofloxacin) 
were more than 90%. This data is consistent with some 
earlier  reports  
18-20
.  In  2012,  Yan  et  al.  showed  that 
antimocrobial resistance of A.baumannii isolates 
increased from 2001 to 2009. The resistance rates to 
aztreonam, ceftazidime, cefotaxim; 
piperacillin/tazobactam, levofloxacin, cefepime were all 
above 75%. Several investigators showed that Less than 
20% of the isolates were sensitive to the majority of 
antibiotics. Decreased susceptibility to the majority of 
antibiotics has been reported previously 
18-20
. 
Studies conducted in other countries, has shown that all 




. Our findings about colistin and tigecycline are in 
accordance with recent data. Although decreased 
susceptibility to colistin and tigecycline among 
A.baumannii isolates has been reported but they can be 
used as effective drugs for treatment of A.baumannii 
infections, but dissemination of A. baumannii resistant to 
colistin is worrying 
21
. 
The carbapenems have been the drug of choice against 
this pathogen, but the number of isolates resistant to 
these antimicrobial agents has considerably increased 
23, 
24. 
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The MIC values for imipenem have been reported 
differently by several researchers. In 2009, Boroumand 
et al. showed that the MIC50 results of imipenem, 
ciprofloxacin, and ceftazidime in 191 clinical isolates of 
A.baumannii were 1.5, 0.5, and >256, whereas and 
MIC90  results of these antibiotics were >32, >32, and > 
256, respectively in Iran 
25
. In this study the percentages 
of A. baumannii isolates resistant to imipenem, 




Another study that were done on 108 A.baumannii 
isolates in Iran by Feizabadi et al. showed that 50.9% 
isolates were resistant to imipenem and rate of MIC50 




In a study conducted in Iraq by Shali et al. the highest 
resistant rate was against ampicillin (100%) while the 
lowest rate was against imipenem (57.1%). The MICs of 
imipenem for the resistant isolates were ≥16 and all 
isolates show multi drug resistance to different 
antibiotics   used.   The   present   study   revealed   that 
imipenem resistant isolates (91.5%) is increasing 
26
. 
Amazian et al., 2006 showed that the percentage of 
imipenem-resistant A. baumannii strains differed among 
countries and ranged from 5.2% in Algeria to 28.8% in 
Tunisia  
27
.  In  2013,  Ramoul  et  al  reported  a  high 
prevalence of imipenem-resistant (91.30%) among 
A.baumannii isolated from two intensive care units 
(ICUs) of two Algerian University hospitals 
28
. Yan et al 
showed that the rate of resistance of A. baumannii to 
imipenem was high (87.8%) in china 2010 
18
. Carvalho 
et al. reported an increased rate of resistant to imipenem 
with MIC50 and MIC90 values 32 µg/ml. 
In comparison to studies performed in Colombia, Brazil, 
Iraq, Algeria, Thailand and china 
17, 18, 19, 23, 26
, a high 
resistance to imipenem was seen in our study. This high 
resistance  to  imipenem  in  Iran  can  be  caused  by 
indiscriminate use of imipenem in the treatment 
A.baumannii infections and acquired OXA-type β- 
lactamases. 
In this study all of isolates were simultaneously resistant 
to at least 3 antibiotics. Our study showed that, 
99(44.8%) isolates were XDR. According to a study 
conducted in Thailand 21.1% of isolates were resistant to 
at least three antibiotics. The frequency of MDR among 
isolates of A. baumannii is increasing. Studies performed 
by several investigators exhibited that resistance to all 
beta-lactam antibiotics (including carbapenems), all 
fluoroquinolones, trimethoprim sulfamethoxazole, and 
most,  if  not all, aminoglycosides  increased  among A. 
baumannii isolates 
29
. A high incidence of MDR strains 
was found in ICU and internal medicine wards in our 
study. It could be attributable to high usage of 
antimicrobials agents in ICU. Continued use of antibiotic 
for treatment of infection should be supported by 
monitoring of antimicrobial susceptibility to prevent the 
spread of resistant isolates and also eliminate the need of 
antibiotics for a prolonged period 
30
. 
The blaOXA -51 gene, considered as a natural component 
of the species chromosome has been used to identify A. 
baumannii 
28
. In accordance to past researches blaOXA -51 
genes are present in the vast majority of isolates of A. 
baumannii and may be associated with resistance to 
carbapenems 
31
. In our study, all strains carried a blaOXA - 
51-like gene and were identified as A. baumannii. 
Most studies showed that percentage of blaOXA types 
varies from one geographic region to another 
28
. In this 
study, all of isolates with blaOXA 23 gene were resistant to 
carbapenem. This result agrees with studies done by Ben 
et al. and Kempf et al. 
2, 23
. 
A study conducted in Taiwan showed that all isolates 
possessed blaOXA 51 genes. None of the strains carried 
blaOXA 23. The coexistences of blaOXA 51/ blaOXA 23 and 
blaOXA 51/ blaOXA 24 genes detected in hospitals B and C 
were  26%  (9/34),  12%  (4/34),  58%  (18/31)  and  3% 
(1/31), respectively 
23
. In China, the frequency of blaOXA 
23, blaOXA 51, blaOXA 58 were reported to be 73%, 12.2% and 




In comparison to studies performed in Spain, Belgium, 
Portugal, the Czech Republic, Georgia, France and the 
USA 
2
, a similar frequency of blaOXA 24 enzymes were 
seen in our study. The existence of blaOXA 58 gene was 
certified in France, Spain, Belgium, Italy, Australia, 
USA 
2, 15, 16, 21
. The co-existence of blaOXA 58 and blaOXA 
23 was detected in 15 (6.8%) isolates and blaOXA 23 and 
blaOXA 24 in 1 (0.5%). There is no co-existence of blaOXA 
24 and blaOXA 58 among isolates. 
Isolates with blaOXA 58 and blaOXA 23 genes were highly 
resistant to imipenem. This result is in accordance with 
that of Raffaele et al. 
12
. Usually, OXA-type enzymes 
exhibit a weak hydrolysis of carbapenems and may not 
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always show resistance profile, but, they may have an 
increase in its expression and show resistance to 







In conclusion, this study has shown that resistance to the 
majority of antibiotics in the population of Acinetobacter 
strains is high with most of isolates showing multidrug 
resistance. Although resistance to carbapenem has been 
seen among our isolates but it seems that carbapenem, 
colistin and tigecycline can be effective drugs for 
treatment of A.baumannii infections. According to our 
findings, piperacillin/tazobactam,  Cefepime, 
ceftazidime, ciprofloxacin, meropenem, 
sulfamethoxazole/trimethoprim, imipenem, ceftriaxone, 
levofloxacin, with resistance more than 90%, are not 
effective drugs for treatment of A.baumannii infections. 
Progressive increase in resistance to the majority of 
antibiotics and multiple resistances in the present study 
may be related to increased usage of these antibiotics for 
treatment of CDI and ability of strains in acquisition of 
resistance genes. Continuous surveillance of 
A.baumannii multidrug-resistant strains is necessary to 
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